Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
RadNet, Inc.
RDNT
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $5.2B
$68.46
▲ +4.32%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$50.76 - $85.84
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 17.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Largest independent outpatient imaging network with 347 centers providing significant scale and operational leverage
- Proprietary AI and software solutions creating recurring revenue streams and customer lock-in
- Established relationships with referring physicians, hospitals, and health systems across seven states
- Integrated platform combining high-volume imaging with technology solutions, difficult for competitors to replicate
Bear Case
2 risks
- Average volatility.
- Extreme premium - high expectations embedded
Growth
Turning profitable
Expansion of AI-powered diagnostic tools driving higher margins and customer stickiness
Value
Extreme premium - high expectations embedded
Momentum
Strong
+19.8% over 3m
Quality
Thin
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying RDNT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 7, 2026
MAY 11, 2026
Reported EPS of -$0.28 vs -$0.14 consensus (-100.0% surprise). Revenue of $575.6M vs $557.9M expected (+3.2%).
EPS surprise · last 4Q
0 of 2 beats
Q2 26
-100.0%
Q2 26
-100.0%
Next: May 7, 2026
Revenue trend · last 8Q
—
—
+13%
+9%
+8%
+13%
+15%
+22%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$459.7M
$461.1M
$477.1M
$471.4M
$498.2M
$522.9M
$547.7M
$575.6M
Margins · last 8Q
Gross
—
Operating
—
Profit
-5.8%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$65.00
▼ -5.1% vs $68.46
Latest: Barclays · $65.00 · May 20, 2026
1 analyst covering